Worcester, MA, June 25, 2010 --(PR.com
)-- The Clinical Pharmacology Study Group (CPSG) is currently participating in several clinical trials for rheumatoid arthritis in their Worcester, MA facility.
Subjects who enroll in a clinical trial are carefully selected from a list of inclusion and exclusion criteria designed to ensure safety for the subject. Patients’ selected to participate in this study are followed by a team of experts in rheumatoid arthritis. All study related medications and care are at no cost to the patient. The study group works closely with the patient care provider (PCP), or other specialist, to ensure that all the medical professionals are involved in the treatment of the patient.
Rheumatoid arthritis is a form of an autoimmune disease. It is a systemic disorder that can impact the entire body and is more common in women than men (3:1). This disease often strikes between 20 and 50 years of age. Rheumatoid arthritis primarily affects joints but problems involving other organs of the body are known to occur. Rheumatoid arthritis can be a very debilitating form of arthritis.
“Total patient care is our top priority at CPSG. We educate and treat the individual about the disease and the study. If our medical team concludes that the patient would be better served with an alternative medical treatment, we will help coordinate that care for patients. We pride ourselves in offering superior patient care throughout the study,” stated Mary Coughlin, RN and Partner of CPSG.
If you want to learn more or enroll in this local study, please contact the:
Clinical Pharmacology Study Group
UMASS Memorial City Campus
26 Queen Street, Worcester, MA 01610
About Clinical Pharmacology Study Group
The Clinical Pharmacology Study Group (CPSG) was established in 1989 in Worcester, Massachusetts by Doctor Birbara and Mary Coughlin, RN. The group has been involved in the field of rheumatology study since 1975. The practice has worked with traditional anti-inflammatory medications (NSAIDs) in conjunction with stomach protecting agents. The group has a history of working with Celebrex, Vioxx, Bextra, and other COX II inhibitors. In the late 1990's, we entered the era of biologicals for the treatment of rheumatoid arthritis (RA).
CPSG is continuing to expand work with biologicals in the areas of rheumatoid arthritis, psoriasis, psoriatic arthritis and Chrohn's disease. CPSG is also participating in many new trials for fibromyalgia, osteoarthritis, osteoporosis, gout, and lower back pain.
Deborah A. Buckley